In pursuit of molecular mechanisms contributing to its implied tumour suppressor activity in ER+ breast cancer, we performed pathway analysis of genes differentially expressed in the ER+ tumours with versus without RUNX1 mutations in TCGA, as well as in the ER+ breast cancer cohort of Ellis et.al. This evidence concerns the gene RUNX1 and breast carcinoma.